We studied the influence of cholestyramine (24 g per day) on receptor-mediated and receptor-independent low-density-lipoprotein catabolism in five women with heterozygous familial hypercholesterolemia. Cholestyramine lowered the level of circulating low-density-lipoprotein apoprotein by doubling (P less than 0.01) its fractional clearance via the receptor path, but fractional catabolism by the receptor-independent route remained unchanged. Moreover, although the absolute rate of catabolism of the apoprotein was not affected by treatment, the amounts handled by each pathway altered. Catabolism via the physiologically controllable receptor route increased by 71 per cent (P less than 0.05), but there was a 12 per cent drop in clearance by the nonreceptor pathway. These data demonstrate the utility of cholestyramine in promoting low-density-lipoprotein catabolism via its specific physiologic clearance pathway. They also show that heterozygotes with familial hypercholesterolemia can increase the activity of their low-density-lipoprotein receptors when presented with an appropriate stimulus.
This article has been cited by other articles:
Staels, B., Fonseca, V. A.
(2009). Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration. Diabetes Care
32: S237-S245
[Full Text]
Walker, J. R., Brown, K., Rohatagi, S., Bathala, M. S., Xu, C., Wickremasingha, P. K., Salazar, D. E., Mager, D. E.
(2009). Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol). J Clin Pharmacol
49: 1185-1195
[Abstract][Full Text]
Claudel, T., Staels, B., Kuipers, F.
(2005). The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism. Arterioscler. Thromb. Vasc. Bio.
25: 2020-2030
[Abstract][Full Text]
Lind, S., Rudling, M., Ericsson, S., Olivecrona, H., Eriksson, M., Borgstrom, B., Eggertsen, G., Berglund, L., Angelin, B.
(2004). Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans. Arterioscler. Thromb. Vasc. Bio.
24: 349-356
[Abstract][Full Text]
Davidson, M. H., Dillon, M. A., Gordon, B., Jones, P., Samuels, J., Weiss, S., Isaacsohn, J., Toth, P., Burke, S. K.
(1999). Colesevelam Hydrochloride (Cholestagel): A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects. Arch Intern Med
159: 1893-1900
[Abstract][Full Text]
Spady, D. K., Cuthbert, J. A., Willard, M. N., Meidell, R. S.
(1998). Overexpression of Cholesterol 7alpha -Hydroxylase (CYP7A) in Mice Lacking the Low Density Lipoprotein (LDL) Receptor Gene. LDL TRANSPORT AND PLASMA LDL CONCENTRATIONS ARE REDUCED. J. Biol. Chem.
273: 126-132
[Abstract][Full Text]
Gaw, A., Packard, C. J., Lindsay, G. M., Murray, E. F., Griffin, B. A., Caslake, M. J., Colquhoun, I., Wheatley, D. J., Lorimer, A. R., Shepherd, J.
(1996). Effects of Colestipol Alone and in Combination With Simvastatin on Apolipoprotein B Metabolism. Arterioscler. Thromb. Vasc. Bio.
16: 236-249
[Abstract][Full Text]
Tilly-Kiesi, M., Mattila, S. P., Tikkanen, M. J.
(1993). Effects of Lovastatin on High-Density Lipoprotein Subfractions in Hypercholesterolemic Patients with Peripheral Vascular Disease. ANGIOLOGY
44: 129-137
[Abstract]
Denke, M. A., Grundy, S. M.
(1990). Hypercholesterolemia in Elderly Persons: Resolving the Treatment Dilemma. ANN INTERN MED
112: 780-792
[Abstract]
Packard, C., Shepherd, J.
(1990). Cholesterol, lipoproteins and atherosclerosis. Vasc Med
1: 91-98
The Lovastatin Study Group III,
(1988). A Multicenter Comparison of Lovastatin and Cholestyramine Therapy for Severe Primary Hypercholesterolemia. JAMA
260: 359-366
[Abstract]
East, C., Bilheimer, D. W., Grundy, S. M.
(1988). Combination Drug Therapy for Familial Combined Hyperlipidemia. ANN INTERN MED
109: 25-32
[Abstract]
ILLINGWORTH, D. R.
(1984). Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia. ANN INTERN MED
101: 598-604
[Abstract]
LaRosa, J. C.
(1982). The Mechanism of Action of Lipid-Lowering Drugs. ANGIOLOGY
33: 562-576
GLUECK, C. J.
(1982). Colestipol and Probucol: Treatment of Primary and Familial Hypercholesterolemia and Amelioration of Atherosclerosis. ANN INTERN MED
96: 475-482
[Abstract]
Brown, M., Kovanen, P., Goldstein, J.
(1981). Regulation of plasma cholesterol by lipoprotein receptors. Science
212: 628-635
[Abstract]
Previous
